TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03341507

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: classical laryngoscopy
Description: the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rigid tube for laryngoscopy
Description: the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
Study: NCT04606095

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)
Study: NCT01982435

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.

Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
Study: NCT03631225

Intervention type: DIAGNOSTIC_TEST
Intervention: Vectra
Description: Each arm will have the Vectra test however, scores will not be provided for the Usual Care Arm until end of study (12 month time point)
Study: NCT02676401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Middle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 High
Study: NCT03202043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose vegetable juice
Description: High dose (13 fl oz) vegetable juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium dose vegetable juice
Description: Medium dose (10 fl oz) vegetable juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose vegetable juice
Description: Low dose (5.5 fl oz) vegetable juice

Intervention type: OTHER
Group type: OTHER
Intervention: Control bottled water
Description: Control (12 fl oz) bottled water
Study: NCT03237273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEAD-US scoring system
Description: HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
Study: NCT02294656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab,
Description: Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
Study: NCT03431584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infiltration of corticosteroids
Description: infiltration of corticosteroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infiltration of corticosteroids and hyaluronic acid
Description: infiltration of corticosteroids and hyaluronic acid
Study: NCT03291509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conference Meetings
Description: Individual video conferencing with a health educator using an iPad.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Meetings
Description: Individual face-to-face (FTF) meetings with a health educator.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Stop Light Diet
Description: Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Stop Light Diet
Description: Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
Study: NCT01234636

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Placebo oil of 4g/day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oil
Description: Placebo oil of 4g/day
Study: NCT02374918

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mTBI wavelength-1 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: mTBI wavelength-2 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HC wavelength-1 bright light
Description: 30 minutes of light exposure

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HC wavelength-2 bright light
Description: 30 minutes of light exposure
Study: NCT02046421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01236963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils mouthrinse
Description: Commercial mouthrinse with manufacturer's use indications
Study: NCT03665844

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartSleep Boost On
Description: SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SmartSleep Boost Off
Description: SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
Study: NCT01916005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Study: NCT04115007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT) + Standard of care
Description: Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).~SBRT is delivered using the following regimen: 30 Grays (10 Gy x 3 fractions) for axial and appendicular bones and lymph node metastases if present. In case the dose cannot be safely delivered while maintaining a safe dose to the organs at risk, an alternate regimen (35 Gy in 5 fractions of 7 Gy) can be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Definition of standard of care (prior to randomization):~* Radiotherapy to the prostate in de novo metastatic patients~* Radiotherapy to the pelvic lymph nodes in patients with positive pelvic nodes (given as full dose to the positive lymph node and prophylactic dose to the pelvic nodal basin)~* Long term ADT +/- intermittent treatment~* Additional therapy following tumor board meeting : new generation hormonal therapy (abiraterone, enzalutamide, apalutamide or other approved) or chemotherapy (docetaxel).
Study: NCT01236963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Floss
Study: NCT03456830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177
Description: ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
Study: NCT00600223

Intervention type: BEHAVIORAL
Intervention: questionnaires and standardized, digital voice recording
Description: Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
Study: NCT03104309

Intervention type: DEVICE
Group type: OTHER
Intervention: Levonorgestrel intrauterine system
Description: Levonorgestrel intrauterine system for adenomyosis
Study: NCT02376322

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
Study: NCT00908089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab
Description: methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
Description: methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
Study: NCT02656576

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tonsil Biopsy
Description: Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Smear
Description: The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
Study: NCT01567358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 100mg/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 100mg/vial
Study: NCT00828308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Prostatectomy 2-8 weeks after completion \*\*\*this was standard of care and not a part of the study\*\*
Study: NCT03291886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entinostat(Placebo)
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Given PO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exemestane
Description: Given PO
Study: NCT02643862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xolair
Description: Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03771430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoarthritis education, exercise and CBT
Description: Osteoarthritis Education~1. 60-min session by AktivA trained PT)~   * Signs/symptoms, risk factors, weight control, treatment~  * Importance of physical activity~  * Appropriate activity \& training modalities~   Exercise and CBT Support~2. 60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~   * Warm-up session~  * Strengthening exercises~  * Functional exercises~  * Stretching~  * Monitoring of CBT progress~  * Review of CBT lessons learned~  * Integration of CBT skills~  * Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~* Pain causes \& prevention~* Pain management~* Health promotion \& stress reduction at home \& work~* Adapting for leisure \& work~* Controlling flare-ups~* Maintaining \& improving results

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Osteoarthritis education, exercise and CBT
Description: Osteoarthritis Education~1. 60-min session by AktivA trained PT)~   * Signs/symptoms, risk factors, weight control, treatment~  * Importance of physical activity~  * Appropriate activity \& training modalities~   Exercise and CBT Support~2. 60-min sessions/week for 12 weeks (a total of 24 sessions) led by AktivA and CBT trained PT)~   * Warm-up session~  * Strengthening exercises~  * Functional exercises~  * Stretching~  * Monitoring of CBT progress~  * Review of CBT lessons learned~  * Integration of CBT skills~  * Enhance motivation to continue~Online CBT (iCBT) (10 modules completed at home)~* Pain causes \& prevention~* Pain management~* Health promotion \& stress reduction at home \& work~* Adapting for leisure \& work~* Controlling flare-ups~* Maintaining \& improving results

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty
Description: Standard total knee arthroplasty will be performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Standard total knee arthroplasty will be performed.
Study: NCT04975022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N11005
Description: oral insulin N11005, 300IU, p.o.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novolin R
Description: reference preparation Novolin R, 0.1 IU/Kg, i.h.
Study: NCT03047928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1/IDO peptide vaccine
Description: The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
Study: NCT01668082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical resection of a brain tumor
Description: The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
Study: NCT03949790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESPB and Intercostal nerve block
Description: Erector spinae plane block + Intercostal nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal nerve block
Description: Intercostal nerve block
Study: NCT01755702

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01105650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).
Study: NCT01645384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets, 40 mg
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin Calcium Tablets, 40 mg
Description: Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Study: NCT02980848

Intervention type: OTHER
Intervention: Screening digital mammography
Description: Screening with digital mammography alone

Intervention type: OTHER
Intervention: Screening digital breast tomosynthesis
Description: Screening with digital mammography plus digital breast tomosynthesis

Intervention type: OTHER
Intervention: Screening breast magnetic resonance imaging
Description: Screening with digital mammography plus breast magnetic resonance imaging

Intervention type: OTHER
Intervention: Diagnostic mammography
Description: Pre-operative diagnostic work-up with mammography alone

Intervention type: OTHER
Intervention: Pre-operative breast magnetic resonance imaging
Description: Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
Study: NCT02210351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI test
Study: NCT03097042

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer any further manipulation
Description: The catheter will be pulled back slowly and without rotation with the plunger still pushed forward

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer with catheter Manipulation
Description: catheter rotation during withdrawal
Study: NCT01223807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing training
Description: The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
Study: NCT03718338

Intervention type: PROCEDURE
Intervention: Evaluation
Description: Undergo clinical evaluations

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04639934

Intervention type: GENETIC
Intervention: MeTree
Description: Software program collecting family health history and generating clinical decision support for risk-based preventive care
Study: NCT01755702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental paracetamol + caffeine formulation
Description: experimental paracetamol + caffeine formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen marketed formulation
Description: ibuprofen marketed formulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol marketed formulation
Description: Paracetamol marketed formulation
Study: NCT00448890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK729327
Description: Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: GSK729327 Matching placebo - Tablets
Study: NCT00758459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1236
Description: oral tablet, 75 mg, twice daily during 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing to match AZD1236
Study: NCT04842578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross- Section of CT Guided Anatomic Segmentectomy
Description: The anatomic segmentectomy is base on the reading and comprehension of Cross- Section of CT.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3D simulation Guided Anatomic Segmentectomy
Description: The anatomic segmentectomy is base on the overview of 3D simulation of pulmonary structure.
Study: NCT00691132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenethyl isothiocyanate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenethyl isothiocyanate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally
Study: NCT01238640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Code STD
Description: 2 mg Single-dose of experimental nicotine product coded STD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Code STE
Description: 2 mg Single-dose of experimental nicotine product coded STE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicorette Microtab
Description: A comparative 2 mg Single-dose of marketed tablet
Study: NCT04440839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine specialty consultation
Description: Patients with lower extremity wounds due to peripheral artery disease and diabetes mellitus will undergo a specialty consultation with a provider through telemedicine
Study: NCT01480596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 10mg/kg IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo IV infusion
Study: NCT01299090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator
Description: two treatments spaced 30 days apart